In a report released on July 30, Nicolas Pauillac from Kepler Capital maintained a Hold rating on GlaxoSmithKline, with a price target of p1,500.00. The company’s shares closed yesterday at p1,418.00.

Pharmaceutical stocks slumped after President Donald Trump sent letters to 17 drugmakers with an ultimatum to reduce drug ...

In the aftermath of the 1971 Liberation War, newly sovereign Bangladesh inherited little industrial infrastructure.

Despite the recent buzz, the effort to reduce animal testing in favor of NAMs has been underway for years. The VQN falls ...

Over 100 employees from GSK’s Hamilton site recently rolled up their sleeves for their annual "Together Days," a volunteer ...

On July 31, the Trump administration told 17 major drugmakers to align U.S. medication prices with the lowest prices sold in other countries, or the most-favored-nation price.  The White House ...

Experts are skeptical that Big Pharma companies will cut prices after President Donald Trump demands Most Favored Nation policies within 60 days.

GlaxoSmithKline Pharmaceuticals to launch oncology assets Jemperli and Zejula in India, addressing critical unmet needs in ...

Merz Aesthetics has revamped its sales and marketing leadership, promoting an employee and hiring a vice president from GSK ...

GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

GLAXOSMITHKLINE PHARMACEUTICALS LTD - Clarification sought from GlaxoSmithKline Pharmaceuticals Ltd - Rediff MoneyWiz, the personal finance service from Rediff.com equips the user with tools and ...

GlaxoSmithKline Pharmaceuticals on Friday said its consolidated net profit increased 12 per cent year-on-year to Rs 279 crore ...